Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
July 2015, Vol 6, No 6
Videos
Managing CCA Patients While Waiting for Molecular Biomarker Testing Results
By
Angela Lamarca, MD, PhD, MSc
;
Vaibhav Sahai, MBBS, MS
;
Milind M. Javle, MD
Interview with the Innovators
,
Cholangiocarcinoma
Videos
Dr Vaibhav Sahai and Dr Angela Lamarca consider options for managing patients with CCA while awaiting results from biomarker testing, which can take 3 to 6 weeks. They discuss starting these patients on first-line chemotherapy and then switching appropriate patients to second-line targeted therapy, and also speak to the increased utility of next-generation sequencing in CCA.
Read Article
Effective Targeted Therapies in CCA: IDH1 and FGFR
By
Milind M. Javle, MD
;
Angela Lamarca, MD, PhD, MSc
;
Vaibhav Sahai, MBBS, MS
Interview with the Innovators
,
Cholangiocarcinoma
Videos
Dr Angela Lamarca reviews the current clinical trials with FGFR inhibitors, particularly those with patients with FGFR2 fusion and other genetic aberrations. Dr Vaibhav Sahai highlights those FGFR inhibitors that are nonselective and those that are selective for FGFR1-4, and discusses the clinical trial results with the selective inhibitors, including pemigatinib and infigratinib. He remarks that the response rates and progression-free survival in these trials have been remarkable, far better than what is seen with chemotherapy.
Read Article
Toxicities Associated with FGFR Inhibitors
By
Milind M. Javle, MD
;
Angela Lamarca, MD, PhD, MSc
;
Vaibhav Sahai, MBBS, MS
Interview with the Innovators
,
Cholangiocarcinoma
Videos
Dr Vaibhav Sahai reviews the toxicities that have been encountered in clinical trials with FGFR inhibitors. He suggests that most of these adverse events are class effects and include hyperphosphatemia (which is relatively easy to manage with dietary restrictions and phosphate-binding agents), nail and hair changes, stomatitis, and retinal epithelial changes. In contrast, Dr Angela LaMarca considers the adverse events associated with chemotherapy, including myelosuppression, nausea, vomiting, diarrhea, and others. Dr Milind Javle suggests that the toxicities encountered with chemotherapy are significantly worse than those with FGFR inhibitors.
Read Article
Using FGFR Inhibitors in Clinical Practice
By
Milind M. Javle, MD
;
Angela Lamarca, MD, PhD, MSc
;
Vaibhav Sahai, MBBS, MS
Interview with the Innovators
,
Cholangiocarcinoma
Videos
Dr Angela Lamarca discusses the use of FGFR inhibitors in daily practice. Their use will depend largely on data from currently ongoing second- and first-line clinical trials. She suggests that consideration should be given to their use in combination with chemotherapy and/or as maintenance therapy after first-line chemotherapy. Dr Milind Javle summarizes the field, suggesting that a time may come when patients with CCA are never treated with chemotherapy at all. Pemigatinib was FDA approved as second-line therapy in cholangiocarcinoma in May 2020.
Read Article
Top 10 Abstracts from ASCO 2020 with Milind Javle
By
Milind M. Javle, MD
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Videos
Treatment options for cholangiocarcinoma continue to evolve. Milind Javle, MD, from MD Anderson Cancer Center, discusses some interesting abstracts from the ASCO 2020 meeting.
Read Article
Telehealth & Oncology During the Fight Against COVID-19 and Its Aftermath
By
Bellinda Conte
;
Ann Ford
;
Femida Gwandry-Sridhar, PhD
;
Nancy Kaszak
;
Lisa Mazur
;
Kenneth Miller, MD
;
Christina Naso
;
Vernessa Pollard
;
Chevon Rariy, MD
;
Burt Zweigenhaft, PhD, D.Litt
AVBCC
Videos
This webinar highlights the ways telehealth can provide the vital and essential care demanded within the field of oncology, with a focus on rural health, palliative care, digital therapeutics, clinical trials, home chemotherapy infusion, and more.
Read Article
Benefits and Challenges of a 2-Sided Risk Model
By
Rani Khetarpal, MBA
Oncology Care Model
Videos
Rani Khetarpal explains what goes into making the decision of moving into a 2-sided risk model along with the benefits and challenges of the model.
Read Article
OCM Payment Methods
By
Rani Khetarpal, MBA
Oncology Care Model
Videos
Rani Khetarpal shares the 3 payment avenues for the Oncology Care Model.
Read Article
How Navigators Improve Care Coordination in OCM
By
Rani Khetarpal, MBA
Oncology Care Model
Videos
Within the Oncology Care Model, the largest costs are attributed to drugs and in-patient hospitalizations. Oncology nurse and patient navigators are essential to reducing emergency room utilization and hospitalizations.
Read Article
OCM's Impact on Improving Access to Care
By
Rani Khetarpal, MBA
Oncology Care Model
Videos
The Oncology Care Model has made a positive impact on improving access and appropriateness to care while keeping the care patient-centered.
Read Article
Page 13 of 19
10
11
12
13
14
15
16
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma